Related Experiment Video
Updated: Feb 1, 2026

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
Diminished myelin-specific T cell activation associated with increase in CTLA4 and Fas molecules in multiple
Dannie E M Hallal-Longo1, Sandra R Mirandola, Elaine C Oliveira
1Neuroimmunology Unit, Department of Microbiology and Immunology, Biology Institute, University of Campinas, UNICAMP, Campinas SP, Brazil.
Abstract:
Multiple sclerosis (MS) is a chronic inflammatory disease of the white matter of the central nervous system (CNS) characterized by focal areas of demyelination. Interferon-beta (IFN-beta) provides an effective treatment that lessens the frequency and severity of exacerbations in relapsing-remitting multiple sclerosis (RRMS), but the mechanisms by which IFN-beta is efficient remain uncertain. The data presented here demonstrate that IFN-beta impairs the proliferative response to myelin basic protein (MBP) and myelin, as well as increasing the expression of the CTLA4 intracellular molecule. Moreover, this treatment increases the expression of surface Fas molecules and of the soluble form of these molecules. Our hypothesis is that the increase in Fas and CTLA4 molecules in MS patients may lead to lymphocyte apoptosis, which suggests possible mechanisms underlying the therapeutic response to IFN-beta.
Insights
Interferon-beta (IFN-beta) treatment for multiple sclerosis (MS) reduces T-cell proliferation and increases CTLA4 and Fas molecules. This suggests a mechanism involving lymphocyte apoptosis, explaining IFN-beta
Area of Science:
- Neuroimmunology
- Central Nervous System (CNS) Disorders
- Inflammatory Diseases
Background:
- Multiple sclerosis (MS) is a chronic CNS inflammatory demyelinating disease.
- Relapsing-remitting MS (RRMS) is treated with interferon-beta (IFN-beta).
- The precise mechanisms of IFN-beta efficacy in MS remain unclear.
Purpose of the Study:
- To investigate the cellular and molecular mechanisms of IFN-beta treatment in MS.
- To explore how IFN-beta affects T-cell responses to myelin antigens.
- To examine the impact of IFN-beta on CTLA4 and Fas molecule expression.
Main Methods:
- Assessing T-cell proliferation in response to myelin basic protein (MBP) and myelin.
- Quantifying the expression of intracellular CTLA4.
- Measuring surface and soluble Fas molecule levels.
Main Results:
- IFN-beta significantly impairs T-cell proliferative responses to MBP and myelin.
- Treatment with IFN-beta increases the expression of intracellular CTLA4.
- IFN-beta elevates both surface and soluble Fas molecule expression.
Conclusions:
- Increased CTLA4 and Fas expression induced by IFN-beta may promote lymphocyte apoptosis.
- This apoptosis of lymphocytes offers a potential explanation for the therapeutic benefits of IFN-beta in MS.
- Understanding these mechanisms could lead to improved MS treatment strategies.
Related Concept Videos
Increasing Function
Molecules with Multiple Chiral Centers
Multiple Allele Traits
Cell Specific Gene Expression
Molecules and Compounds
Nervous Tissue: Myelin
Schwann cells begin to form myelin sheaths around axons during fetal development. They wrap around a small...

